Bronchiectasis is a clinical condition defined as a chronic, abnormal dilation of the bronchi accompanied by classical ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

The global Chronic Obstructive Pulmonary Disease (COPD) treatment market is projected to experience steady growth over the ...

Dupilumab, an injectable interleukin (IL)-4 and IL-13 pathway inhibitor, recently received FDA approval as the first-ever ...

The increasing demand for asthma treatment is largely driven by the rising number of asthma cases. Factors such as increased smoking and air pollution are impairing lung function and contributing to ...

Oct. 2, 2024 — The FDA has approved Regeneron and Sanofi’s drug Dupixent for patients with COPD (chronic obstructive pulmonary disease). Marking the sixth indication for the drug, the approval ...

The FDA has granted a supplementary approval to Regeneron and Sanofi’s dupilumab (Dupixent) for use as an add-on therapy for inadequately controlled chronic obstructive pulmonary disease (COPD ...

Dupixent is now cleared for use as an add-on maintenance treatment for adults with a certain kind of chronic obstructive pulmonary disease, or COPD, that can’t be controlled with other medications.

Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, has identified improvements in patient outcomes from the TOviTO® clinical trial program, involving more than 16,000 Chronic ...